Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eileen M Boyle

Showing results (21-30 of 52) with videos related to

Pageof 6
Sort By:
Ejhaem|October 6, 2025
The Role of Radiotherapy for Patients With Multiple Myeloma in the Modern Era: A Real World Single-Centre ExperienceDipal Mehta, Maria Gabriel, Nathan Adu-Poku, et al.
Blood Cancer Journal|May 31, 2022
Structural variants shape the genomic landscape and clinical outcome of multiple myelomaCody Ashby, Eileen M Boyle, Michael A Bauer, et al.
Frontiers in Immunology|February 11, 2022
Extracellular Vesicles as Biomarkers of Acute Graft-vs.-Host Disease After Haploidentical Stem Cell Transplantation and Post-Transplant CyclophosphamideGiuseppe Lia, Clara Di Vito, Stefania Bruno, et al.
Nature Communications|August 28, 2021
Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myelomaKylee H Maclachlan, Even H Rustad, Andriy Derkach, et al.
Frontiers in Oncology|October 17, 2025
Current quality of life questionnaires are not relevant for assessing QOL issues in multiple myeloma patients in the era of modern therapies: results from a survey with myeloma patients and myeloma healthcare professionalsCatherine S Y Lecat, Sotirios Bristogiannis, Dipal Mehta, et al.
British Journal of Haematology|August 28, 2014
MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndromeStéphanie Poulain, Eileen M Boyle, Christophe Roumier, et al.
Oncotarget|September 20, 2017
<i>BACH2</i> promotes indolent clinical presentation in Waldenström macroglobulinemiaCharles Herbaux, Elisabeth Bertrand, Guillemette Marot, et al.
Haematologica|May 28, 2017
The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myelomaAneta Mikulasova, Christopher P Wardell, Alexander Murison, et al.
Seminars in Cell & Developmental Biology|May 7, 2021
Chromothripsis as a pathogenic driver of multiple myelomaFrancesco Maura, Eileen M Boyle, Even H Rustad, et al.
Geroscience|October 1, 2024
Inflammation and aging-related disease: A transdisciplinary inflammaging frameworkBrian J Andonian, Joseph A Hippensteel, Katrina Abuabara, et al.
Pageof 6

Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
Ejhaem|October 6, 2025
The Role of Radiotherapy for Patients With Multiple Myeloma in the Modern Era: A Real World Single-Centre ExperienceDipal Mehta, Maria Gabriel, Nathan Adu-Poku, et al.
Blood Cancer Journal|May 31, 2022
Structural variants shape the genomic landscape and clinical outcome of multiple myelomaCody Ashby, Eileen M Boyle, Michael A Bauer, et al.
Frontiers in Immunology|February 11, 2022
Extracellular Vesicles as Biomarkers of Acute Graft-vs.-Host Disease After Haploidentical Stem Cell Transplantation and Post-Transplant CyclophosphamideGiuseppe Lia, Clara Di Vito, Stefania Bruno, et al.
Nature Communications|August 28, 2021
Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myelomaKylee H Maclachlan, Even H Rustad, Andriy Derkach, et al.
Frontiers in Oncology|October 17, 2025
Current quality of life questionnaires are not relevant for assessing QOL issues in multiple myeloma patients in the era of modern therapies: results from a survey with myeloma patients and myeloma healthcare professionalsCatherine S Y Lecat, Sotirios Bristogiannis, Dipal Mehta, et al.
British Journal of Haematology|August 28, 2014
MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndromeStéphanie Poulain, Eileen M Boyle, Christophe Roumier, et al.
Oncotarget|September 20, 2017
<i>BACH2</i> promotes indolent clinical presentation in Waldenström macroglobulinemiaCharles Herbaux, Elisabeth Bertrand, Guillemette Marot, et al.
Haematologica|May 28, 2017
The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myelomaAneta Mikulasova, Christopher P Wardell, Alexander Murison, et al.
Seminars in Cell & Developmental Biology|May 7, 2021
Chromothripsis as a pathogenic driver of multiple myelomaFrancesco Maura, Eileen M Boyle, Even H Rustad, et al.
Geroscience|October 1, 2024
Inflammation and aging-related disease: A transdisciplinary inflammaging frameworkBrian J Andonian, Joseph A Hippensteel, Katrina Abuabara, et al.
Pageof 6